The NINDS Small Business Program provides support to small businesses to develop products addressing unmet clinical and research needs.
Here we present company information about a small number of awardees ready to attract third-party collaborators and investors.
AXONIS Therapeutics is advancing breakthrough drug discoveries to develop a pipeline of first-in-class neuron-reviving therapeutics for neurological disorders, to make a real difference for patients, their families, and the global healthcare system.
AXONIS Therapeutics Executive Summary(pdf, 198 KB)
Chemeleon has created a platform technology for an instrument-free, in vitro diagnostic assay that provides a rapid, visible, colorimetric readout in minutes for the detection of cerebrospinal fluid leaks at the point-of-care that will be extended to an array of other markets and analytes (ex., viruses, proteins, drugs, etc.)
Chemeleon Executive Summary(pdf, 250 KB)
Eysz Inc., is building a digital health platform for neurology - starting with Epilepsy - that will analyze eye-movement data to reliably quantitate seizures and neurocognitive symptoms to enable clinicians to deliver personalized medicine for their patients.
Eysz Executive Summary(pdf, 1092 KB)
Great Lakes NeuroTechnologies, the leader in remote monitoring of movement disorders, markets KinesiaU™, enabling doctors to provide personalized, efficient, accurate therapy titration with fewer office visits, saving time and money.
Great Lakes Neurotechnologies Executive Summary(pdf, 275 KB)
Rumi Scientific's platform makes it faster and more predictive to perform drug discovery in the CNS by identifying compounds which reverse the disease state at the cellular and tissue levels in large scale screenings, resulting in novel and better targets in the neurodegenerative and neurodevelopmental areas.
Rumi Scientific Executive Summary(pdf, 172 KB)
South Rampart Pharma is committed to improving the lives of people suffering from acute, neuropathic and chronic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in current over the counter and prescription medicines.
South Rampart Pharma Executive Summary(pdf, 521 KB)